Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus TROP2 ADC for TNBC Brain Metastases
NCT06793332Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Dec 2024
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in triple-negative breast cancer (TNBC), sponsored by Fudan University. Primary endpoint: Intracranial Objective Response Rate at 12 weeks. Started Dec 2024; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06793332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793332.